Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQC3302 Inhalation Spray in Healthy Adult Subjects
NCT07267130Phase 1Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Nov 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of TQC3302 in chronic obstructive pulmonary disease (COPD) (9 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Treatment Emergent Adverse Event and The subject with abnormal security check. Started Nov 2025; status: terminated.
02
Drugs
TQC3302
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07267130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07267130.